Search Results for: treatment

CMTA’s $450K Investment Targets New Approach to Treatment for Patients with CMT1A and CMT1B

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth (CMT) disease research aimed at bringing treatments to patients, announced today an investment of $450K into a new scientific approach…

CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C

…urgent need for new treatments for these patients.” We celebrate this encouraging news from Actio Biosciences and look forward to the continued progress in bringing effective treatments to those affected…

Consensus_Statement_on_Surgical_Treatment_of_CMT

…the success or fail- ure of their treatment? A history of genetic testing should be noted. Although not required for surgical treatment, the CMT genotype may be helpful in better…

Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A

Shift Pharmaceuticals, CMTA Partner on ASO Treatment for CMT1A GLENOLDEN, PENNSYLVANIA, USA, NOVEMBER 3, 2022 — Shift Pharmaceuticals, a privately held company that is developing antisense oligonucleotides (ASOs) to treat…

Data Shows Benefit with PXT3003 in Patients with CMT1A

…treatments. Pharnext has two lead products in clinical development. PXT3003 completed an international Phase III trial with encouraging topline results for the treatment of Charcot-Marie-Tooth disease type 1A (‘CMT1A’) and…

CMT1A Ionis Press Release

New Research Shows Promise for CMT Progressive Neuromuscular Disease Potential treatment offers hope for over 2.8 million affected worldwide Glenolden PA, December 4, 2017—A new paper published December 4th on…

A Cure for Caroline and Other CMT Stories

Caroline’s journey with a rare and serious form of CMT began when she was just 9 months old. Today, a cure for Caroline may open the door to treatments and…

Webinar Recordings

…spent the last decade specializing in treatment of adults with acquired neurological impairments. She is certified in neuro-developmental treatment and the use of physical agent modalities. She has specialty training…

Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

…Deficiency patients, AT-007 reduced blood sorbitol levels by approximately 66% from baseline through 30 days of treatment. The range of reduction from baseline in patients was 54%-75%. AT-007 was safe…

CMTA-STAR Biotech & Alliance Partners

…the development of innovative therapeutics harnessing the Integrated Stress Response (ISR) for the treatment of a broad range of diseases. The company plans to demonstrate the clinical effectiveness of its…